GSK Phase II Win Offers Hope For TB Breakthrough
Second Antibiotics Success For UK Major This Month
Results from a Phase II trial have demonstrated the potential of GSK's first-in-class antitubercular agent to be a component of simpler treatment regimens for tuberculosis in the future.
